Currently, adjuvant medical therapy with aromatase inhibitors (AIs) for BC is considered appropriate for an initial duration of 5 years, according to the National Comprehensive Cancer Network (NCCN) Panel3. This evidence concerns the gene CYP19A1 and breast cancer.